ReviewInternational journal of inflammation2023
Irisin and Cardiometabolic Disorders in Obesity: A Systematic Review.
Review in International journal of inflammation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 15 citations in OpenAlex.
- Evaluation of Serum Irisin, Leptin, Adiponectin, Resistin, and Galectin-3 Levels and Their Relationship with Ultrasonographic Subcutaneous Fat Thickness in Patients with Lipedema.Aesthetic plastic surgery · 2026Article
- Fall-Related Physical Function, Executive Function, and Myokine Responses in Older Women with Obesity Participating in a 16-Week Combined Aquatic Exercise Program: A Prospective Observational Study.Medicina (Kaunas, Lithuania) · 2026Observational
- White Tea Modulates Metabolic Parameters and Adipokine Signaling in Experimental Obesity: Evidence for Functional Food Potential.International journal of molecular sciences · 2026Article
- Inflammation-Insulin Resistance Crosstalk and the Central Role of Myokines.International journal of molecular sciences · 2025Review
- Crosstalk between skeletal muscle and the brain during physical activity - in search of epigenetic mechanisms.Epigenetics · 2025Review
- Exploring irisin levels in patients with endometrial atypical hyperplasia and carcinoma: a comparative analysis.BMC cancer · 2025Article
- Identification of candidate nsSNPs of the human FNDC5 gene and their structural and functional consequences using in silico analysis.Scientific reports · 2025Article
- The Regulatory Effects of Exercise and Metformin on Biomarkers in Obesity: A Focus on Uric Acid, Irisin, Adiponutrin, Adropin, and Copeptin.Medicina (Kaunas, Lithuania) · 2025Article
- Article
- Metabolic Syndrome, Thyroid Dysfunction, and Cardiovascular Risk: The Triptych of Evil.International journal of molecular sciences · 2024Review
- Trajectory of Irisin as a Predictor of Kidney-Related Outcomes in Patients with Asymptomatic Heart Failure.Biomedicines · 2024Article
- A multidisciplinary obesity registry for Iranian adults: a protocol.Journal of diabetes and metabolic disorders · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Overweight and obesity are global health issues, impacting a significant portion of young adults. Obesity is a complex condition influenced by genetics and environmental factors, leading to increased susceptibility to cardiovascular diseases (CVDs), hypertension, dyslipidemia, and insulin resistance. Irisin, a protein derived from the cleavage of fibronectin type III domain-containing protein 5, may have relationship with these cardiometabolic diseases. Objective: This systematic review aims to examine the relationship between serum irisin levels and obesity, particularly in individuals predisposed to cardiovascular risk factors. Methods: A thorough literature search was conducted in multiple databases, including "Science Direct," "Scopus," "PubMed," and "Lilacs," from July 2020. Inclusion criteria encompassed subjects with metabolic disorders (with or without obesity, BMI ≥30 kg/m Results: Out of 151 identified articles, 30 met the inclusion criteria. These studies, published between 2013 and 2020, assessed adults (≥21 years) and included 26 observational studies and 4 clinical trials ( Conclusion: The review suggests that irisin plays a significant role as both a preventive measure and a biomarker for comorbidities linked to obesity and cardiometabolic disorders. Future research should focus on standardized irisin measurement methods and diverse populations to further elucidate its mechanisms of action.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.